509
Participants
Start Date
July 1, 2020
Primary Completion Date
March 5, 2021
Study Completion Date
April 16, 2021
ABX464
ABX464 50mg QD for 28 days + Standard of Care
Placebo
Placebo 50mg QD for 28 days + Standard of Care
Centre hospitalier Saint Pierre, Brussels
Hôpital Erasme, Brussels
UZ Gent, Ghent
Asklepios Klinik St. Georg, Hamburg
Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico - Infectious Diseases, Milan
Ospedale San Paolo, Milan
Ospedale Luigi Sacco, AO-PU, Milan
Ospedale Niguarda, Milan
Asklepios Klinik Altona, Hamburg
Ospedale A. Manzonidi Lecco - ASST Lecco, Lecco
Hospital de La Princesa, Madrid
Hospital Universitario Infanta Leonor, Madrid
Ospedale di Vittorio Veneto - Medecina generale, Vittorio Veneto
Universitätsklinikum Bonn, Bonn
Centro de Prevención y Rehabilitación de Enfermedades Pulmon, Nuevo León
Universitätsmedizin Mannheim Ruprecht-Karls-Universität Heid, Mannheim
Hôpital Saint-Antoine, Paris
Hôpital Nord, Amiens
Centre Hospitalier Départemental de Vendée, La Roche-sur-Yon
Consultorio médico, Mérida
Fundacao de Medicina Tropical Doutor Heitor Vieira Dourado - Instituto de Pesquisa Clínica Carlos Borborema, Manaus
Centro Oncológico de Roraima - CECOR - NAP, Boa Vista
Hospital das Clinicas da FMUSP, São Paulo
Instituto Nacional de Infectologia Evandro Chagas - FIOCRUZ Rio de Janeiro, Rio de Janeiro
Conjunto Hospitalar do Mandaqui, São Paulo
Centre Hospitalier Universitaire de Nice, Nice
Hospital Universitari Germans Trias i Pujol, Badalona
H.G.U. Alicante, Alicante
Hospital del Mar, Barcelona
Royal Free Hospital, London
Lead Sponsor
Abivax S.A.
INDUSTRY